ArticleThe New England journal of medicine2015
Why is there no generic insulin? Historical origins of a modern problem.
Article in The New England journal of medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Response to a Critique: Errors with Acri's Opinion Piece Defending IP, While Premature Deaths Pile Up from Patents.Health care analysis : HCA : journal of health philosophy and policy · 2026Article
- Insulin Rationing Persists Despite Policy Changes: Repeated Cross-Sectional Studies, 2017 vs 2024.Journal of general internal medicine · 2025Article
- An Empirical Review of Key Glucose Monitoring Devices: Product Iterations and Patent Protection.Journal of diabetes science and technology · 2025Review
- Lessons From Insulin: Policy Prescriptions for Affordable Diabetes and Obesity Medications.Diabetes care · 2024Review
- Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986-2019.PLoS medicine · 2023Article
- The commercialisation of insulin.Anaesthesia and intensive care · 2023Article
- The Nuances Surrounding Insulin Prescribing.Clinical diabetes : a publication of the American Diabetes Association · 2023Article
- Patent "Evergreening" of Medicine-Device Combination Products: A Global Perspective.Healthcare policy = Politiques de sante · 2022Article
- Can nutrition interventions tackle the global insulin affordability via improving diabetes management and reducing insulin demand?Global health research and policy · 2022Article
- Real-World Impact of Switching From Insulin Glargine (LantusFrontiers in public health · 2022Article
- A global perspective on the issue of access to insulin.Diabetologia · 2021Review
- A Decade of Disparities in Diabetes Technology Use and HbADiabetes care · 2021Article
- "Life or death": Experiences of insulin insecurity among adults with type 1 diabetes in the United States.SSM - population health · 2020Article
- Origins of the Crisis in Insulin Affordability and Practical Advice for Clinicians on Using Human Insulin.Current diabetes reports · 2020Review
- Access to insulin: applying the concept of security of supply to medicines.Bulletin of the World Health Organization · 2019Article
- Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006-2018.JAMA · 2019Article
- Medicaid Eligibility Expansions May Address Gaps In Access To Diabetes Medications.Health affairs (Project Hope) · 2018Article
- Type 1 diabetes.Lancet (London, England) · 2018Review
- Tertiary patenting on drug-device combination products in the United States.Nature biotechnology · 2018Article
- Production costs and potential prices for biosimilars of human insulin and insulin analogues.BMJ global health · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.